Evaluating Patterns and Factors Related to Sleep Disturbances in Prostate Cancer Patients

Abstract

Prostate cancer patients may experience disturbed sleep as a result of their diagnosis or treatment. This study sought to evaluate disturbed sleep and excessive daytime sleepiness in newly diagnosed patients and those receiving androgen deprivation therapy (ADT). This study was conducted with 74 patients. Subjective data using the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) and actigraphy data on ADT/ADT-naïve patients were collected. The prevalence of poor sleep quality, determined from PSQI and ESS scores, was 50% and 16.7% respectively. Those on ADT (n = 20) had poorer sleep quality as determined by significantly higher PSQI scores (70 vs. 40% scoring > 5) and were more likely to have poor sleep quality, sleep latency, and sleep efficiency than ADT-naïve patients (n = 40). Actigraphy data showed that ADT patients slept significantly longer (7.7 vs. 6.8 h), experienced a higher Fragmentation Index (48.3 vs. 37.4%), and had longer daytime nap duration (64.1 vs. 45.2 min) than ADT-naïve patients. The use of objective measures such as actigraphy in the clinical arena is recommended and may be used as a valuable tool for research into sleep assessment in prostate cancer patients.

Understanding Sleep Disturbances in Prostate Cancer—A Scientometric Analysis of Sleep Assessment, Aetiology, and Its Impact on Quality of Life

“…The collective use of actigraphy and subjective sleep questionnaires is both feasible and relatively inexpensive in a clinical setting to assess sleep profiles that can serve as a platform for conducting larger clinical trials. This has been corroborated in our own institutional feasibility study of 74 patients with prostate cancer [121].…”

Comparison of Frailty Criteria, Cognitive Function, Depressive and Insomnia Symptoms in Men with Localized and Advanced Prostate Cancer under Androgen Deprivation Therapy

“…A scoping review which analyzed the prevalence of frailty syndrome in mPCa found that 70% of patients with mPCa were frailer than localized patients [27]. We also propose to evaluate the role of other geriatric variables such as depressive symptoms and insomnia, given that studies have linked androgen depletion to depressive symptoms and/or insomnia in men without prostate cancer [28][29][30][31] and in patients with prostate cancer [32][33][34]. Since frailty has been related to age, polypharmacy, and overweight, we also analyzed the contribution of these variables.…”